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Abstract
Background: The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has
been reported frequently but no clear relationship between APLA and the clinical and neuroimaging
features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS
patients with plasma APLA.
Methods: A consecutive cohort of 24 subjects with relapsing-remitting (RR) MS were studied of whom
7 were in remission (Rem) and 17 in exacerbation (Exc). All subjects were examined and underwent MRI
of brain. Patients' plasma was tested by standard ELISA for the presence of both IgM and IgG antibodies
using a panel of 6 targets: cardiolipin (CL), β2 glycoprotein I (β2GPI), Factor VII/VIIa (FVIIa),
phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethanolamine (PE).
Results: In exacerbation up to 80% of MS subjects had elevated titers of IgM antibodies directed against
the above antigens. However, in remission, less than half of MS patients had elevated titers of IgM
antibodies against one or more of the above antigens. This difference was significant, p < 0.01, for all 6
target antigens. Interestingly, none of the MS patients had elevated plasma titers of IgG against any of the
target antigens tested. Correlation analysis between MRI enhancing lesions and plasma levels of APLA
revealed high correlation for aPC, aPS and aFVIIa (p ≤ 0.0065), a trend for aPE and aCL (p = 0.056), and
no correlation for aβ2GP1. The strongest correlation was for aFVIIa, p = 0.0002.
Conclusion: The findings of this preliminary study show that increased APLA IgM is associated with
exacerbations of MS. Currently, the significance of this association in pathogenesis of MS remains
unknown. However, systematic longitudinal studies to measure APLA in larger cohorts of patients with
relapsing-remitting MS, particularly before and after treatment with immunomodulatory agents, are
needed to confirm these preliminary findings.
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Background
Multiple sclerosis (MS) is an immune-mediated neurode-
generative disorder of human central nervous system,
which is initially characterized by loss of myelin/oli-
godendrocyte complex followed by progressive neuronal
loss and axonal degeneration [1-3]. Clinically, the major-
ity of MS patients present with a relapsing-remitting
course and within a few years, a large number of these
patients with or without treatment with immunomodula-
tory agents enter another phase of disease known as sec-
ondary progressive MS. Neuropathologically, MS lesions
within MS are characterized by perivenular infiltration of
myelin basic protein-activated CD4 T lymphocytes as well
as reactive macrophages which orchestrate the massive
inflammatory cascade within the CNS [2]. Another arm of
the immune system, the humoral immune system-
autoantibodies as well as activated complement system-
also play a significant role in the pathogenesis of MS [2,3].
The abnormal activation of both cellular and humoral
immune arms combined with disruption of the blood
brain barrier (BBB), activation of the cerebral endothelial
cells, and loss of adjacent tight and adherent endothelial
junctions [4-6] precede formation of perivenular demyeli-
nating lesions
The first antiphospholipid antibody (APLA) identified
was anti-cardiolipin (aCL) in 1941, seen in false-positive
syphilis tests. The lupus anticoagulant (LAC), which is
believed to be a manifestation of APLA, was originally
associated with a hemorrhagic diathesis [7,8] but in the
1980s, a stronger association with thrombosis was found,
first called aCL syndrome or Hughes syndrome, now
known as antiphospholipid syndrome (APS) [9-12]. A
major advance was the realization that nearly all APLA are
in fact directed not against phospholipids (PL) per se, but
against PL-binding proteins [13]. The first such cofactor
identified was β2GPI, said to be associated with thrombo-
sis, but many others were subsequently identified, now
numbering in the dozens. This discovery has greatly
broadened the definition of APLA, and makes clear that
APLA detected by standard ELISA methods are in reality
very heterogeneous [14,15].
High frequencies of APLA are seen in autoimmune disor-
ders other than systemic lupus erythematosus (SLE), not
necessarily associated with thrombosis, such as in the
bleeding disorder, immune thrombocytopenic purpura
(ITP) [16] and in MS.
The neuropsychiatric manifestations of APLA (with or
without APS) are well known [17,18] and in some
instances resemble those of MS [19-23]. The reported fre-
quencies of positive APLA in MS have ranged from 10% or
less [24-26] to 44% [27] and to 88% [20]. Such wide dis-
crepancies are common in the APLA literature and are
attributable to variations in methodological details
(which are inadequately specified in some of the above
cited reports) as well as criteria of patient selection such as
distinguishing clinical state. To our knowledge, no report
to date has established a clear association between APLA
and the clinical state or radiologic imaging data in MS
patients. The present study was motivated to clarify these
uncertainties using the same standardized methods we




The study was approved by the Institutional Review Board
of Louisiana State University Health Sciences Center in
Shreveport, Louisiana and all subjects provided their
signed informed consent forms. We measured plasma
APLA in a cohort of 24 subjects with relapsing-remitting
MS (RRMS) defined by the revised McDonald criteria
[30], of whom 17 were in exacerbation (Ex) and 7 in
remission (Re). None of the study subjects had any other
medical disorders or causes (other autoimmune disor-
ders, drug abuse, taking certain medications such as anti-
biotics, hydralazine, procainamide or other inflammatory
disorders) that could explain positivity for APLA. None of
the female study subjects had any history of spontaneous
abortions or stroke-like syndromes. Exacerbation was
defined as the appearance, the reappearance or the wors-
ening of symptoms of neurological dysfunction lasting
more than 24 hours preceded by at least one month of sta-
bility from the last relapse. All subjects were recently diag-
nosed and treatment-naive. In parallel, we also measured
APLA in 21 healthy subjects (controls) with no prior his-
tory of immune-mediated disorders.
Imaging methods
Brain MRI was performed using a 1.5 T machine with a
standard quadrature head coil. The image protocol
included sagittal T1-, axial T1-, T2-weighted, and fluid
attenuated inversion recovery (FLAIR) images. Sagittal T1-
Weighted: 550/10 ST:5 mm, Acq matrix:256 × 192; Axial
T1-weighted 700/10 ST: 5 mm Acq matrix 256 × 192;
Axial T2GRE> 550/15 ST:5 mm; Dual echo (T2WI/PD).
3000/140/14 ST:5 mm Acq matrix 256 × 224. All MRI
images of the brain were obtained pre- and post-intrave-
nous infusion of single dose of Gd-DTPA. We performed
qualitative analysis of axial T2-weighted and pre- and
post-contrast axial T1-weighted images for evaluation of
MS lesions. The MR images were independently analyzed
by a neuroradiologist blinded to patients' clinical data.
Identification of MS lesions was made by visual inspec-
tion as was determination of the enhancing versus non-
enhancing lesions. Computer based software allowed
comparison of the lesions among different groups. Sub-
jects were subgrouped into those with versus without axialBMC Neurology 2007, 7:36 http://www.biomedcentral.com/1471-2377/7/36
Page 3 of 7
(page number not for citation purposes)
T1-weighted at least one contrast enhancing lesions in
order to determine any correlation between the presence
of APLA and the presence of contrast-enhancing lesions.
Measurement of APLA
1. Sample handling
Blood was collected in blue-top Vacutainers (citrate), cen-
trifuged at 4500 rpm for 15 min, and plasma was frozen
at -20 until assay. We use plasma not serum to avoid
potential loss of some antibodies in the clot. Upon
defrosting, samples were again centrifuged and 1:50 dilu-
tions were made in PBS-Tween as described [28].
2. Materials
Phospholipids were obtained from Sigma Chemicals (St.
Louis, MO). Purified β2GPI and factor VII were obtained
from Enzyme Research Laboratories (South Bend, IN), or
activated recombinant factor VII (rFVIIa, NovoSeven)
from NovoNordisk, A/S (Bagsvaer, Denmark). Commer-
cial kits for assay of aCL and β2GPI were obtained from
INOVA Diagnostics, San Diego, CA (Cat. No's. 708625,
708630, 708665, 708670 for aCL IgG, IgM and aβ2GPI
IgG, IgM, respectively).
3. Target antigens
IgG and IgM APLA were assayed by ELISA for β2GP-I and
factor VII/VIIa (FVII/VIIa), a novel APLA antigen [28]. In
addition, reactivities against four pure phospholipids (PL)
were measured: cardiolipin (CL), phosphatidylcholine
(PC), phosphatidylserine (PS), and phosphatidyle-
thalonamine (PE).
4. ELISA methodology
Guidelines of the European Consensus [31,32] were
observed in development of the aCL assay, and similar
methodology for the other tests, as detailed previously
[28,29]. Our methodology was validated with commer-
cial kits approved by the Federal Drug Administration
(FDA) for aCL and aβ2GPI, identified above. The kits
included calibrator mAb and gave good agreement
between our results and known positive and negative
samples furnished with the kits. Since the particular pro-
tein target antigens (or cofactors) in plasma are unknown
for the four PL tested (CL, PC, PS PE), we estimated titers
by the OD ratio method described below.
5. Normal control values and cutoff points
To have a constant reference for calculating optical density
(OD) ratio, pooled plasma from 21 normal volunteers
was used, termed the quality control (QC) sample. The
OD of this QC plasma was used as the denominator for
calculating the OD ratio: OD of patient sample/OD of QC
plasma. To determine normal ranges, we tested 50 healthy
subjects (32 female, 18 male) of age range 25–60 years, by
the same OD ratio method and set the positive cutoff at 2
SD above the mean. Only 1 of 50 normal controls was
found outside this range (IgG for β2GPI and CL). Results
did not differ substantially if the cutoff was set at 3 SD.
Each plate was run with one QC plasma sample and usu-
ally with an additional individual normal control, all in
duplicate.
Statistical analyses
All statistical analyses were performed using StatMost 32
software. Comparisons for significant differences were
determined by chi squared test. Correlations were evalu-
ated in terms of the Pearson correlation coefficient. Signif-
icance was accepted if p < 0.05. In case of multiple
analyses (6 APLA tests), then the Bonferroni adjustment
may apply. The standard of significance changes from
0.05 to 0.0083 (= 0.05/6) for each test.
Results
Demographic features of MS subjects are presented in
Table 1. The study subjects with RRMS consisted of 20
females and 4 males with a mean duration of neurological
symptoms prior to diagnosis of 5.3 months. None of the
MS subjects had ever experienced any thromboembolic or
thrombo-occlusive syndromes.
The principal finding of this study was a much higher fre-
quency of APLA positive test results for MS patients in
exacerbation compared to remission. Figure 1 shows
graphically the results for subjects with IgM antibodies
against the pure phospholipids (PL). It is observed that
the increased frequency of seropositivity ranged from 2-
fold to 4-fold in exacerbation compared to remission. This
was statistically significant in every case at p < 0.004. Inter-
estingly, no positive IgG was encountered.
It is apparent that if all patients were combined rather
than separated by exacerbation vs. remission, the fre-
quency of positive tests would be reduced. For example,
on the basis of all 24 patients, the prevalence of aPS was
54% and that of aFVII was 41.6% (not shown).
Figure 2 shows positive results for the two protein anti-
gens, β2GPI and FVII/VIIa. Both of these autoantibodies
Table 1: Demographic features of MS subjects
Exacerbation Remission
No 17 7
Age 23 ± 4 24 ± 3
Female/Male 13/4 6/1
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were significantly and more frequently present in exacer-
bation compared to remission, p = 0.004. Remarkably,
none of the patients in remission exhibited seropositivity
for anti-FVII but 10 of 17 (59%) in exacerbation were pos-
itive.
A summary of frequency of seropositivity of APLA in MS
patients and controls is shown in Table 2. Plasma of 19 of
our MS subjects tested positive in at least one of the 12
tests (6 antigens, IgG and IgM). All these antibodies were
of IgM family. No positive IgG was detected. The right-
most bar of Figure 2 shows frequency of at least one posi-
tive of the 12 tests between exacerbation and remission.
This difference was also significant (p < 0.01).
Next, we analyzed possible correlations between the pres-
ence of T1-weighted post contrast enhancing lesions on
brain MRI and the presence of various sub-classes of
APLA. Results are shown on Table 3. A significant correla-
tion between contrast-enhancing lesions and 3 of the 6
target antigens (FVII, PC, PS) was found (p < 0.0002,
0.0065, 0.0014, respectively). There was a trend toward
correlation for anti-PE and anti-CL (p = 0.056 for both).
Interestingly, there was no trend of correlation for anti-
β2GPI.
Discussion
The central finding of this paper is a close association
between APLA and certain clinical and neuroradiologic
features of MS. We surmise that previous studies failed to
detect this association because they did not distinguish
clinical states of the patients, or used methods unable to
make this discrimination.
The frequency of MS plasma positive for APLA in this
study was higher than in most but not all previous reports,
since as noted in the introduction, Ijdo and colleagues
found 88% positivity [20]. The number of tests performed
on each specimen in our study was larger than most and
would help to increase the likelihood of finding at least
one positive test in a given subject. Furthermore, few if
any prior studies clearly separated exacerbation from
remission, resulting in a reduced apparent prevalence,
since we clearly show a much greater frequency of positiv-
ity in exacerbation.
Our finding of IgM exclusively (no IgG) was also unex-
pected but is not entirely inconsistent with prior reports
since most find a preponderance of IgM over IgG. For
example, Sugiyama et al found 14 of 32 positive for IgM
but only 3 of 32 positive for IgG [27]. It is unlikely that
our finding of exclusively IgM reflects a systematic meth-
odological error since other studies in progress at the same
time (such as of ITP) revealed nearly equal numbers of
IgG and IgM seropositivity. Additionally, another recent
study on clinical and neuroimaging correlates of autoreac-
tive antibodies in MS patients revealed similar finding
[33]. Through a retrospective study, the investigators
determined that APLA mainly of IgM type was present in
55% of their study subjects with MS. It remains unknown
now why, in our MS subjects, exclusively IgM APLA was
Comparison of positive APLA-IgM antibodies (IgM-Ab) in MS  subjects, for β2 glycoprotein-I (B2GP-I), factor VII/VIIa (FVII/ VIIa) and for at least one of the 6 measured antigens, in exac- erbation versus remission Figure 2
Comparison of positive APLA-IgM antibodies (IgM-Ab) in MS 
subjects, for β2 glycoprotein-I (B2GP-I), factor VII/VIIa (FVII/
VIIa) and for at least one of the 6 measured antigens, in exac-
erbation versus remission.
Comparison of positive IgM antibodies (IgM-Ab) in MS sub- jects, for phospholipids antigens, in exacerbation versus  remission Figure 1
Comparison of positive IgM antibodies (IgM-Ab) in MS sub-
jects, for phospholipids antigens, in exacerbation versus 
remission. Abbreviations: CL = cardiolipin, PC = phosphati-
dylcholine, PS = phosphatidylserine, PE = phosphatidyleth-
anolamine.BMC Neurology 2007, 7:36 http://www.biomedcentral.com/1471-2377/7/36
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found; however, we hypothesize that since the subjects in
this study were all newly diagnosed they had not yet class-
switched to IgG. Alternatively, one may suggest that a
class-switching occurs in a small fraction of APLA+ MS
patients, but majority of these APLA+ MS patients are
defective in class-switching [34].
The clinical significance of the findings of this study is
unknown; however, there are two broad possibilities: first,
that APLA in MS may contribute causally to the disease
pathogenesis, or that APLA are secondary (epiphenome-
nal) with no role in promotion of the inflammatory cas-
cade of MS. Regarding the first concept, it is important to
point out that our assay of aPC, aPS, aPE and aCL does not
identify the specific plasma antigen responsible for a pos-
itive test. As remarked in the introduction, many APLA
antigens are now known, and certainly many more exist,
therefore it is possible that APLA in MS are directed
against some specific antigen that could be involved, for
example, in compromise of the BBB. A number of availa-
ble reports document cross-reaction of some APLA with
endothelial cells and platelets [35-39], raising the possi-
bility that the rise of specific types of APLA in the MS sub-
jects could trigger exacerbations by further compromise of
the BBB. We have shown complex effects of plasma from
MS patients on brain microvascular endothelial cells in
tissue culture [40,41].
It should be stressed that our assay against the four pure
phospholipids will detect any PL-binding protein, not
necessarily those thus far identified as APLA. It is therefore
possible that we are detecting an antigen specifically
involved in compromise of the BBB, possibly responsible
for the endothelial activation that we reported in exacer-
bations of MS [42].
It is of interest that only anti-β2GPI, which is believed to
be a risk factor for thrombosis, was not associated with MS
radiologic imaging, while anti-FVII was most closely asso-
ciated (Table 2). The pathophysiological significance of
these findings remain unclear but it may be relevant to
note that FVIIa is closely associated with tissue factor (TF),
FXa, and TF pathway inhibitor (TFPI) in normal hemosta-
sis, and that TF has numerous actions apart from throm-
bosis and hemostasis [43].
In light of these findings, further investigation of APLA in
a larger cohort of MS subjects is warranted to clarify the
Table 3: Correlations of APLA with MRI enhancing lesions
Pearson
APLA Corr. Coeff. p value
FVII IgM 0.686 0.0002
PC IgM 0.529 0.0065
PS IgM 0.602 0.0014
PE IgM 0.387 0.056
CL IgM 0.380 0.056
β2GP-I IgM 0.220 0.29
After converting patients' positivity and negativity data of APLA and MRI lesions into numeric "1" and "0", respectively, Pearson correlation analysis 
was performed.
Abbreviations: VIIa = Factor VIIa; PC = phosphatidylchlorine; PS = phosphatidylserine; PE = phosphatidylethanolamine; CL = cardiolipin; β2-GP-I = 
β2-glycoprotein-I
Table 2: Frequency of positivity of APLA in MS and controls
Target antigens Exacerbation Remission Controls
IGG IGM IGG IGM IGG IGM
β2-GP-I 0/17 (0%) 14/17 (82%) 0/7 (0%) 2/7 (28%) 1/21 (4%) 0/21 (0%)
VIIa 0/17 (0%) 10/17 (59%) 0/17 (0%) 0/7 (0%) 0/21 (0%) 0/21 (0%)
CL 0/17 (0%) 14/17 (82%) 0/17 (0%) 2/7 (28%) 0/21 (0%) 0/21 (0%)
PC 0/17 (0%) 13/17 (76%) 0/17 (0%) 1/7 (14%) 0/21 (0%) 0/21 (0%)
PS 0/17 (0%) 12/17 (71%) 0/17 (0%) 1/7 (14%) 0/21 (0%) 0/21 (0%)
PE 0/17 (0%) 14/17 (82%) 0/17 (0%) 2/7 (28%) 0/21 (0%) 0/21 (0%)
At least one 0/17 (0%) 15/17 (88%) 0/17 (0%) 4/7 (57%) 1/21 (4%) 0/21 (0%)
The abbreviations: β2-GP-I = β2-glycoprotein-I; VIIa: Factor VIIa; CL = cardiolipin; PC = phosphatidylcholine; PS= phosphatidylserine; PE = 
phosphatidylethanolamineBMC Neurology 2007, 7:36 http://www.biomedcentral.com/1471-2377/7/36
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significance of these autoantibodies in MS. Further under-
standing the role of these autoantibodies in MS subjects
may eventually translate into more effective treatments.
Conclusion
The findings of this preliminary study demonstrate pres-
ence of IgM APLA during exacerbations of MS. Currently,
the significance of these autoantibodies in pathogenesis
of MS remains unknown. Longitudinal studies to measure
both IgM and IgG classes of APLA in larger cohorts of
patients with relapsing-remitting MS are necessary to
establish the significance of these autoantibodies and
assess their pattern of expression before and after treat-
ment with disease modifying agents.
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